Suzuko Moritani

No ORCID on file · 4 papers in corpus
lab-animal 2025
Human cell ·doi:10.1007/s13577-025-01176-0

Only a few human ovarian endometrioid carcinoma cell lines are currently available, partly due to the difficulty of establishing cell lines from low-grade cancers. Here, using a cell immortalization strategy consisting of i) inactivation of…

case-report 2025
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.16253

Cesarean scar defect (CSD) is a long-term complication of cesarean section (CS). However, its risks for perimenopausal women remain unclear. We present a rare case of CSD involving hematometra in a perimenopausal woman, which led to emergen…

other 2022
Cancer biomarkers : section A of Disease markers ·doi:10.3233/cbm-210435

BACKGROUND: Ovarian clear cell carcinomas (OCCCs) have been recurrent and refractory among the present treatments, so novel therapeutics are urgently needed. OBJECTIVE: The present study accumulates the proof of concept to examine the feas…

case-report 2021
Gynecologic oncology reports ·doi:10.1016/j.gore.2020.100684

•We report the first case of a paraurethral mixed Müllerian cystadenoma.•The cystic lesion was lined by a mixture of three different types of epithelium.•All epithelial cells were positive for estrogen receptor and PAX8.